Page last updated: 2024-12-07

micronomicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

micronomicin: DE 020 & DE 020 eyedrops both consist of KW 1062, benzalkonium chloride, sodium chloride, sodium hydroxide & distilled water pH 7.4; RN given refers to parent cpd; see also record for gentamicin C; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3037206
CHEMBL ID373081
CHEBI ID81283
SCHEMBL ID147893
MeSH IDM0113544

Synonyms (48)

Synonym
xk-62-2
gentamicin c2b
kw 1062
micromycin
sagamicin (obs.)
de 020
antibiotic kw 1062
gentamicin c(sub 2b)
micromicin
micronomicinum [inn-latin]
o-2-amino-2,3,4,6-tetradeoxy-6-(methylamino)-a-d-erythro-hexopyranosyl-(1-4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1-6))-2-deoxy-d-streptamine
d-streptamine, o-2-amino-6-(methylamino)-2,3,4,6-tetradeoxy-alpha-d-erythro-hexopyranosyl-(1-4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1-6))-2-deoxy-
micronomicin
micronomicine [inn-french]
6'-n-methylgentamicin c(sub 1a)
d-streptamine, o-2-amino-2,3,4,6-tetradeoxy-6-(methylamino)-alpha-d-erythro-hexopyranosyl-(1-4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1-6))-2-deoxy
xk 62-2
antibiotic xk 62-2
micronomicin [inn]
micronomicina [inn-spanish]
micronomicin (dcf)
C17706
D08219
(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(methylaminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
micronomicina
micronomicine
micronomicinum
6'-n-methylgentamicin c1a
chebi:81283 ,
CHEMBL373081
AKOS016010141
unii-s9az0r40qv
s9az0r40qv ,
micronomicin [who-dd]
o-2-amino-2,3,4,6-tetradeoxy-6-(methylamino)-.alpha.-d-erythro-hexopyranosyl-(1->4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl-(1->6)-2-deoxy-d-streptamine
o-2-amino-2,3,4,6-tetradeoxy-6-(methylamino)-a-d-erythro-hexopyranosyl-(1->4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl-(1->6))-2-deoxy-d-streptamine
micronomicin [mi]
SCHEMBL147893
DNYGXMICFMACRA-XHEDQWPISA-N
DB13274
Q6839784
HY-B1915
CS-0013973
DTXSID401023736
(2r,3r,4r,5r)-2-{[(1s,2s,3r,4s,6r)-4,6-diamino-3-{[(2r,3r,6s)-3-amino-6-[(methylamino)methyl]oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol
EN300-19766347
gtpl12162
(2r,3r,4r,5r)-2-(((1s,2s,3r,4s,6r)-4,6-diamino-3-(((2r,3r,6s)-3-amino-6-((methylamino)methyl)tetrahydro-2h-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-5-methyl-4-(methylamino)tetrahydro-2h-pyran-3,5-diol

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No accumulations nor adverse clinical reactions due to the drug occurred in treatment at a dose level of 360 mg daily for 5 days in each of the 2 patients."( [Study of efficacy and safety of micronomicin administered by intravenous drip infusion in treatment against complicated urinary tract infections].
Suzuki, K; Takanashi, K, 1987
)
0.27
" These data suggest that MCR is sufficiently safe in ototoxicity within dose of 120 mg/day for 4 days."( [Ototoxicity of micronomicin sulfate--audiometric assessment].
Hohzawa, K; Shibuya, M; Yuasa, R, 1983
)
0.27
" There was no adverse effect on fertility ability at any dose."( [Safety evaluation of micronomicin VII. Fertility study by intravenous injection in rats].
Deguchi, T; Fujita, T; Hara, T; Takahashi, H, 1983
)
0.27
" There was no adverse effect on new borns at any dose."( [Safety evaluation of micronomicin VIII. Teratogenicity studies in rabbits after intravenous injection].
Deguchi, T; Fujita, T; Hara, T; Takahashi, H, 1983
)
0.27
" There was no adverse effect on delivery and nursing ability in dams at any dose."( [Safety evaluation of micronomicin IX. Perinatal and postnatal study by intravenous injection in rats].
Deguchi, T; Fujita, T; Hara, T; Takahashi, H, 1983
)
0.27
" There was no adverse effect on new borns at any dose."( [Safety evaluation of micronomicin. III. Teratogenicity studies in rats].
Hara, T; Miyazaki, H; Nishikawa, S; Ohguro, Y, 1983
)
0.27

Pharmacokinetics

ExcerptReferenceRelevance
"Following the previous report on pharmacokinetics of micronomicin (MCR) in healthy volunteers, pharmacokinetic studies were made again in patients with different degree of renal impairment, and a nomogram was obtained."( [Clinical studies of intravenous drip infusion of micronomicin. 1. Pharmacokinetics (Part 2). Intravenous Micronomicin Research Group].
Kawaguchi, Y; Koyama, M; Mitsuhashi, S; Saito, I; Watanabe, M, 1985
)
0.27
" The pharmacokinetic studies of MCR after intramuscular or drip intravenous administration were carried out using one-compartment open model or two-compartment open model, respectively."( [Pharmacokinetic studies on micronomicin in rats. Comparison of intramuscular and drip intravenous administration models].
Deguchi, T; Inoue, A; Kobayashi, H; Kurimoto, T; Okachi, R, 1983
)
0.27
" The pharmacokinetic parameters (T1/2, AUC, Kel, Vd and Cl) of MCR except Cmax and Tmax were not differentiated by the route of administration."( [Pharmacokinetic studies on micronomicin in dogs. Comparison of intramuscular and drip intravenous administration models].
Deguchi, T; Hara, T; Inoue, A, 1983
)
0.27

Dosage Studied

ExcerptRelevanceReference
") data obtained from multiple dosing in man was done using a non-linear least-squares regression program MULTI."( Three-compartment open model analysis of micronomicin in man.
Kaneniwa, N; Mashimo, K; Matsumoto, M; Watanabe, M, 1986
)
0.27
" From these results, a nomogram for the optimum dosage regimen of MCR was obtained."( [Clinical studies of intravenous drip infusion of micronomicin. 1. Pharmacokinetics (Part 2). Intravenous Micronomicin Research Group].
Kawaguchi, Y; Koyama, M; Mitsuhashi, S; Saito, I; Watanabe, M, 1985
)
0.27
"0 micrograms/ml when the dosage was 120 mg."( [Clinical studies of intravenous drip infusion of micronomicin. 1. Absorption and excretion].
Koyama, M; Watanabe, M, 1983
)
0.27
" There was a little larger difference in AUC between those 2 routes of administration but the differences seemed negligible when the same dosage was used."( [Clinical studies of intravenous drip infusion of micronomicin. 1. Absorption and excretion].
Koyama, M; Watanabe, M, 1983
)
0.27
"KW-1062, a new aminoglycoside antibiotic, was tested for the evaluation of audiotoxicity in administration at higher dosage and compared with the audiotoxicity of gentamicin."( [Animal test for evaluation of ototoxicity and safety of KW-1062 (author's transl)].
Akiyoshi, M; Hara, T, 1980
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aminoglycoside
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (72)

TimeframeStudies, This Drug (%)All Drugs %
pre-199062 (86.11)18.7374
1990's2 (2.78)18.2507
2000's2 (2.78)29.6817
2010's5 (6.94)24.3611
2020's1 (1.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (6.76%)5.53%
Reviews3 (4.05%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other66 (89.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]